Company Outlook & Guidance: In the API sector, a positive shift in the export landscape is anticipated in the near future, supported by interest rate reductions, low stock levels, and an upswing in demand. We have BUY on stock

Aarti Drugs Ltd. is trading below all available SMAs

Aarti Drugs Ltd.

29 Jan 2024

386.65

0.49%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Axis Direct

It is expected that API's realisations could be on lower side along elevated key solvents as the industry is facing oversupply.

Number of FII/FPI investors increased from 73 to 83 in Sep 2025 qtr.

Aarti Drugs Ltd.

20 Oct 2023

386.65

0.49%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We expect demand for API to continue in the upcoming quarters with easing supply chain bottlenecks. We believe that Aarti Drugs, being a leader in the domestic industry, is well-placed to capitalize on prevalent as well as future growth opportunities.

Number of FII/FPI investors increased from 73 to 83 in Sep 2025 qtr.

Aarti Drugs Ltd.

25 Jul 2023

386.65

0.49%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We believe that Aarti Drugs, being a leader in the domestic industry, is well-placed to capitalize on prevalent as well as future growth opportunities. We have BUY rating on stock.

Number of FII/FPI investors increased from 73 to 83 in Sep 2025 qtr.

Is Aarti Drugs Ltd. worth buying?

748 Votes:

Buy 77.81%

Sell 11.36%

Hold 10.83%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf